6533b86dfe1ef96bd12ca907

RESEARCH PRODUCT

Experience in the long term use of new antiarrhythmic drugs.

Norbert TreeseWolfgang KasperZehender MThomas G. HofmannA. GeibelThomas MeinertzTiberius Pop

subject

AdultMalemedicine.medical_specialtyLidocainePropafenonePharmacologyLorcainidePiperidinesInternal medicineMexiletineIdiopathic dilated cardiomyopathymedicineHumansPharmacology (medical)cardiovascular diseasesMyocardial infarctionFlecainideAgedFlecainidebusiness.industryArrhythmias CardiacMiddle Agedmedicine.diseasecardiovascular systemCardiologyFemaleDisopyramidebusinessAnti-Arrhythmia Agentsmedicine.drug

description

Meinertz et a1. (1984) investigated the long term efficacy and tolerability of flecainide in patients with ventricular arrhythmias. 15 patients were studied, 8 women and 7 men, aged 19 to 74 (mean 58.7) years, with more than 30 ventricular premature complexes (VPCs) per hour, and ventricular arrhythmias of Lown grade IVA or IVB. 11 had coronary artery disease and 2 had idiopathic dilated cardiomyopathy. Patients were excluded on the basis of sustained ventricular tachycardia (VT) [defined as ~ 3 consecutive beats at a rate of> 100 beats/min]; myocardial infarction within the last 6 months; unstable angina; severe congestive heart failure; or conduction abnormalities. Previously unsuccessful antiarrhythmic treatments included: mexiletine (13 patients), propafenone (11), disopyramide (9), lignocaine (lidocaine) [4], lorcainide (3) and ajmaline (5).

yearjournalcountryeditionlanguage
1985-01-01Drugs
10.2165/00003495-198500294-00006https://pubmed.ncbi.nlm.nih.gov/4006777